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Adventitial lymphatic capillary 
expansion impacts on plaque T cell 
accumulation in atherosclerosis
Timo Rademakers1,*, Emiel P. C. van der Vorst1,2,*, Isabelle T. M. N. Daissormont1,*, 
Jeroen J. T. Otten1, Kosta Theodorou1, Thomas L. Theelen1, Marion Gijbels1,3,4, 
Andrey Anisimov5, Harri Nurmi5, Jan H. N. Lindeman6, Andreas Schober2, Sylvia Heeneman1, 
Kari Alitalo5 & Erik A. L. Biessen1,7
During plaque progression, inflammatory cells progressively accumulate in the adventitia, paralleled 
by an increased presence of leaky vasa vasorum. We here show that next to vasa vasorum, also the 
adventitial lymphatic capillary bed is expanding during plaque development in humans and mouse 
models of atherosclerosis. Furthermore, we investigated the role of lymphatics in atherosclerosis 
progression. Dissection of plaque draining lymph node and lymphatic vessel in atherosclerotic ApoE−/− 
mice aggravated plaque formation, which was accompanied by increased intimal and adventitial 
CD3+ T cell numbers. Likewise, inhibition of VEGF-C/D dependent lymphangiogenesis by AAV aided 
gene transfer of hVEGFR3-Ig fusion protein resulted in CD3+ T cell enrichment in plaque intima and 
adventitia. hVEGFR3-Ig gene transfer did not compromise adventitial lymphatic density, pointing to 
VEGF-C/D independent lymphangiogenesis. We were able to identify the CXCL12/CXCR4 axis, which 
has previously been shown to indirectly activate VEGFR3, as a likely pathway, in that its focal silencing 
attenuated lymphangiogenesis and augmented T cell presence. Taken together, our study not only 
shows profound, partly CXCL12/CXCR4 mediated, expansion of lymph capillaries in the adventitia 
of atherosclerotic plaque in humans and mice, but also is the first to attribute an important role of 
lymphatics in plaque T cell accumulation and development.
Human and experimental murine atherosclerosis are both hallmarked by chronic inflammation. Several immune 
cell types, including macrophages, T and B cells, mast cells, and dendritic cells (DCs), are thought to be involved 
in the development and progression of an atherosclerotic plaque1–5. Although inflammatory responses are largely 
confined to the intimal plaque itself, there is growing evidence for a crucial role of the adventitia in vascular 
inflammation and plaque development6.
The adventitia is a highly organized tissue harboring stromal cells, vessels and, in particular in atherosclerosis, 
(resident) leukocyte subsets7–13. The overt presence of DC-T cell clusters in adventitia suggests a role as scaffold 
for antigen presentation12,14. Adventitial vessels, the vasa vasorum, expand with atherosclerosis progression both 
in humans and in mice, and have important functions in inflammatory cell trafficking, amongst others10,15–17.
The adventitia is therefore increasingly viewed as an important gateway for leukocytes, such as T cells10, to the 
plaque, a notion referred to as the “outside-in” hypothesis17. As we have previously shown, adventitial vessels were 
more leaky than similarly sized vessels in other organs, potentially causing interstitial fluid buildup, the drainage 
of which requires functional lymphatics18. Indeed next to vasa vasorum, the adventitia of human atherosclerotic 
vessels was recently reported to accommodate an extensive lymphatic capillary network19,20, at a density that 
increased with disease severity19,20. The perivascular lymphatic bed exerts several critical functions, not only in 
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interstitial fluid drainage, but also in reverse cholesterol transport from plaque to liver21, and in cell trafficking in 
and out of tissues22–24. This suggests an important, but so far unresolved, contribution of adventitial lymphatics to 
plaque inflammation and atherosclerosis.
In this study, we have addressed the role of adventitial lymphatic capillaries in a murine model of atherosclero-
sis by two independent loss-of-function approaches. Our results show augmented T cell accumulation after inhib-
iting lymph drainage or VEGFR3 dependent lymphangiogenesis, suggesting that the lymphatic capillaries are 
responsible for T cell drainage from the atherosclerotic lesion. Furthermore, we identified the CXCL12/CXCR4 
axis as an important regulator of adventitial lymphangiogenesis.
Results
Lymphatic capillaries are present in the adventitia of human and mouse atherosclerotic lesions 
at densities that increase with plaque progression. Previous work by us and others already showed 
that the adventitial vasculature (aka vasa vasorum) expands with atherosclerosis progression15–18, and that these 
vasa vasora are dysfunctional and leaky. Conceivably the enhanced presence of leaky vessels will cause local 
edema, unless the tissue is properly drained by lymphatics. As lymphangiogenesis and angiogenesis are respon-
sive to partly overlapping cues, this led us to investigate whether adventitial lymphatic vessels expand in response 
to the atherosclerotic stimulus as well.
Hereto we immunohistochemically screened a cohort of atherosclerotic human aortic artery segments 
obtained by autopsy, for the presence of adventitial lymphatics. Lymphatic capillaries were abundantly present in 
the adventitia of human atherosclerotic lesions and their presence was substantially increased in advanced and 
ruptured lesions compared to non-diseased or early atherosclerotic tissue (Fig. 1A,B). Apparently the pattern of 
adventitial lymphangiogenesis mirrors that in intimal lesions19,20. Next we investigated whether lymphangiogen-
esis also occurs in mouse atherosclerosis. The adventitia of atherosclerotic carotid artery segments from ApoE−/− 
mice featured both vasa vasorum and lymphatic capillaries (Fig. 1C, red and blue, respectively; Suppl. Fig. 1). 
The lymphatic capillary density in the adventitia was considerably increased at week 4 and remained high at later 
stages of plaque development (Fig. 1D), suggesting that lymphatic expansion occurs already at an early stage of 
atherogenesis.
Lymph node and lymph vessel dissection deteriorates atherosclerosis development in ApoE−/− 
mice by promoting T cell accumulation inside the lesion and adventitia. The increased presence 
of lymph vessels in the adventitia of human and mouse atherosclerotic lesions, together with the fact that lymph 
vessels have been implicated in the regulation of interstitial fluid drainage and inflammation25,26, argue for an 
important role for lymph capillaries in atherosclerosis. We therefore studied the impact of dissecting the plaque 
draining lymph vessels and lymph node on atherosclerosis development in ApoE−/− mice. We opted for the deep 
Figure 1. Increased presence of adventitial lymphatic capillaries during human and mouse atherosclerosis 
development. (A) Immunohistochemical staining of podoplanin+ (D2-40) lymphatic capillaries (Brown) in 
human aortic atherosclerotic lesions obtained during kidney transplantation (10x magnification, Insert = 20x 
magnification). *Shows CD31+ adventitial microvessels (blue). (B) Quantification of adventitial lymph vessel 
density (LVD) in different stages of human atherosclerotic lesion development. (C) Immunohistochemical 
staining of Lyve-1+ lymphatic capillaries (Purple) and CD31+ vasa vasorum (Blue) in mouse carotid 
atherosclerotic lesions. Continued line indicates the outer border of the media; the area between the continuous 
and dotted line indicates the adventitial area used for quantification (10x magnification, Insert = 20x 
magnification). (D) Quantification of the percentage Lyve-1+ lymphatic capillaries per adventitial area of 
different stages of mouse lesion development.
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cervical lymph node, which is most proximal to the carotid artery bifurcation, and its efferent vessel, running 
in parallel to the carotid artery (Fig. 2A). Lymph node dissection by itself did neither influence body weight, 
plasma cholesterol levels (Suppl. Fig. 2A,B) nor induce local inflammation in the adventitia, as judged by the 
unchanged vascular CD45+ leukocyte contents in lymph node dissected mice (Fig. 2B). Lymph node dissection 
did not affect body weight (29.23 ± 0.48 g and 27.64 ± 0.52 g in control versus lymph node dissected mice, respec-
tively). Interestingly, dissection aggravated atherosclerotic plaque burden (Fig. 2C,D). No significant changes 
Figure 2. Lymph node dissection results in an aggravation of plaque development in mice, characterized 
by an accumulation of CD3+ T cells within the vessel wall. (A) Draining lymph node and efferent vessel were 
excised in the lymph node dissection group. (B) Percentage of CD45+ leukocytes in the adventitia of control 
and lymph node dissected (LD) mice. (C) Representative pictures of Hematoxylin-Eosin-stained sections of 
the carotid arteries from control and lymph node dissected mice. Quantification of (D) plaque volume, (E) 
plaque classification and (F) routine pathological examination of plaque composition. Percentage of Mac-3+ 
macrophages in the plaques (G). Percentage of CD3+ T cells in (H) plaque and (I) adventitia. (J) Percentage of 
Lyve-1+ lymphatic capillary area in the adventitia.
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were found in progression stage or gross composition (Fig. 2E,F). Although plaque macrophage content remained 
unaltered (Fig. 2G), atherosclerotic plaques displayed increased intimal (Fig. 2H) and adventitial CD3+ T cell 
content (Fig. 2I). Circulating monocyte numbers (Suppl. Fig. 2C) and peripheral lymph node T cell content 
(Suppl. Fig. 2D) were unchanged, again illustrating the local reach of the intervention. Lymph node dissection 
and thus interruption of drainage did not have any effects on lymphatic capillary bed density in the adventitia 
(Fig. 2J) at endpoint (4 weeks after lymph node dissection), although origin and functionality of these newly 
formed capillaries could not be assessed. No differences were observed in vasa vasorum development upon lymph 
node dissection (Suppl. Fig. 2E). Altogether, these data point to a role of adventitial lymphatic vasculature in 
drainage of plaque derived T cells and/or of T cell targeting chemokines and cytokines from the plaque, translat-
ing in reduced T cell but not macrophage accumulation in the plaque, thus dampening plaque growth.
Inhibition of lymphangiogenesis using an AAV-hVEGFR3-Ig construct did not change plaque 
burden, yet increased lesional T cell content. Lymph node dissection did not alter atherosclerosis asso-
ciated adventitial lymph vessel expansion, suggesting that these newly formed lymphatics are not originating 
from the main efferent lymph node that runs in parallel to the carotid artery. As this potentially points towards 
a role of lymphangiogenic factors, we next sought to address the contribution of the major driver of postnatal 
lymphangiogenesis, VEGF-C/D, to adventitial neolymphangiogenesis by AAV aided transfer of IgG-fused soluble 
human VEGFR3 (AAV-hVEGFR3-Ig)27, which inactivates VEGF-C/D. Gene therapy led to persistent overexpres-
sion of soluble hVEGR3 in serum of treated but not control mice, as assessed by western blotting (Fig. 3A) and 
ELISA (Fig. 3B). As expected, the achieved sVEGFR3 levels were sufficient to halt the lymphangiogenic response 
in an in vivo VEGF-C supplemented Matrigel plug assay, as illustrated by the sharp reduction in lymph vessel 
ingrowth (Fig. 3C). AAV gene therapy did not alter body weight or plasma cholesterol levels (Suppl. Fig. 3A,B), 
nor did it affect circulating monocyte numbers (Suppl. Fig. 3C) or peripheral lymph node T cell content 
(Suppl. Fig. 3D). Moreover it did not change plaque volume (Fig. 3D), stage (Fig. 3E) and composition (Fig. 3F). 
However, plaques of AAV-hVEGFR3-Ig treated mice did show a more inflammatory phenotype, with increased 
adventitial and intimal CD3+ T cell content (Fig. 3G). Much to our surprise, while halting systemic lymphang-
iogenesis in the matrigel plug assay, hVEGFR3 overexpression failed to inhibit adventitial lymphatic capillary 
expansion (Fig. 3H). No effects of hVEGFR3-Ig treatment were observed on intimal or adventitial microvessels 
(Suppl. Fig. 3E). Collectively, in both the systemic lymphangiogenesis intervention study and the LN dissection 
study, we observed a striking increment in lesional T cell content, pointing to a role of plaque-associated lymph 
vessels in regulating local T cell content.
Plaque-associated lymph vessels are partly derived from non-classical lymphangiogenesis via 
the CXCL12/CXCR4 axis. As observed, surgical interruption of lymph drainage as well as gene therapeutic 
inhibition of lymphangiogenesis by AAV-hVEGFR3-Ig, both affected plaque T cell accumulation, possibly by 
attenuating their drainage from plaque (or by reducing their recruitment). However, interfering with the classical 
VEGF-C/D-VEGFR3 pathway of lymphangiogenesis by using the AAV-hVEGFR3-Ig did not abrogate lymph 
vessel development at plaque adventitia (Fig. 3H), suggesting a role for non-canonical lymphangiogenic backup 
factors, that come into play once the VEGF-C/D pathway fails. A chemokine pathway that has been implicated in 
VEGFR3 independent lymphangiogenesis is the CXCL12/CXCR4 pathway28,29. This chemokine axis has already 
been shown to promote lymphangiogenesis in murine models of corneal neovascularization or cancer28,29. 
Additionally, CXCL12 has been shown to be a chemoattractant for lymphatic endothelial cells29. To address the 
involvement of CXCR4 signaling in lymph vessel expansion, we have silenced its ligand CXCL12 in adventitia, at 
plaque initiation, by local perivascular administration of pluronic gel containing siCXCL12. CXCL12 silencing 
resulted in a significant 42% reduction in adventitial lymph vessel density, underpinning the causal role that 
CXCR4/CXCL12 plays in atherosclerosis associated lymph vessel expansion (Fig. 4A). In further support of a role 
of plaque lymphangiogenesis in T-cell accumulation, CD3+ T cells were increased after siRNA CXCL12 targeting, 
at borderline significance (Fig. 4B).
Together, this experiment shows that the lymph angiogenesis is at least partly mediated by CXCL12/CXCR4.
Human plaque data confirms correlations between lymph vessel density and the CXCR4/
CXCL12 axis. To confirm a potential role of the local lymphatic vessels in T cell trafficking in humans, 
we performed correlation analysis between the number of T cells and the local lymph vessel area in human 
carotid endarterectomy plaque tissue. First, we were able to show a tight correlation between D2-40 staining 
area in human plaque and mRNA expression of lymphatic markers LYVE-1 and podoplanin (the target of 
D2-40) (Suppl. Fig. 4). Correlation analysis showed a clear inverse correlation between the amount of T cells 
and lymph vessel presence in human tissue (Fig. 5A). This correlation seemed to be cell type specific, as mac-
rophages did not show any correlation with the amount of lymph vessel presence (Fig. 5B). As described, we 
found that the CXCL12/CXCR4 axis at least partly mediates the effects on lymph angiogenesis in mice. Indeed 
also in human tissue we found a substantial correlation between CXCR4 mRNA expression and lymph vessel 
presence in human carotid endarterectomy plaque tissue (Fig. 5C), arguing for a link of the CXCR4 axis with 
plaque lymphangiogenesis.
In conclusion, our data implicate the CXCR4 rather than VEGF-C/D axis in atherosclerosis associated lym-
phangiogenesis and identified the regulatory role of adventitial lymphatics in plaque T-cell homeostasis.
Discussion
In this study, we describe a role for adventitial lymphatic capillaries in plaque inflammation and atherosclerosis 
in mouse and human. As we show, the adventitial lymphatic capillary bed is markedly expanded early on in ath-
erogenesis. Surgical interruption of lymphatic plaque drainage prior to atherogenesis aggravated atherosclerosis 
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development, with increased T cell accumulation in plaque and adventitia as most prominent feature. The lat-
ter was also observed after systemic inhibition of VEGFR3-dependent lymphangiogenesis. Interestingly, both 
interventions did not impact lymph capillary bed density in the adventitia or plaque, suggesting that adventitial 
lymphatic expansion is not originating from the carotid lymph vessel, and driven by alternative VEGF-C/D inde-
pendent (backup) mechanisms, possibly through the CXCR4/CXCL12-axis.
As we show, during atherosclerosis, vasa vasorum expansion goes hand in hand with that of the adventitial 
lymphatic capillary bed. This concurs with previous findings showing progression stage dependent increases in 
lymphatic capillary content in human carotid artery plaque19,20, and with the recent observation that lymphatic 
dysfunction precedes the onset of atherosclerosis30. Interestingly, inhibition of VEGFC/D dependent lymphang-
iogenesis did, in contrast to lymph node/efferent dissection, not affect the atherosclerotic burden, while increas-
ing adventitial and plaque CD3+ T cell content. Conceivably, systemic hVEGFR3‐dependent lymphangiogenesis 
blockage may initially reduce the draining capacity, eliciting alternative VEGFR3 independent lymphangiogene-
sis pathways in plaque tissue, such as mechano‐induced β 1-integrin signaling31, or the CXCL12-CXCR4 axis28,29. 
In support of the latter Bot et al. previously observed elevated CXCR4 expression in atherosclerotic lesions, 
Figure 3. Soluble hVEGFR3 gene therapy did not affect plaque burden and plaque-associated 
lymphangiogenesis, yet induced an increase in plaque T cell content. (A) Western blot showing cropped 
image of blot and (B) ELISA analysis of hVEGFR3 expression in plasma after AAV-hVEGFR3-Ig gene transfer. 
(C) Lymph vessel formation and ingrowth in an in-vivo matrigel plug assay, four weeks after s.c. administration 
of AAV-hVEGFR3-Ig gene transfer. Quantification of (D) plaque volume, (E) plaque classification and 
(F) routine pathological examination of plaque composition of lesion formation in carotid arteries. (G) 
Quantification of adventitial and plaque T cell content. (H) Percentage of Lyve-1+ lymphatic capillary area in 
the adventitia.
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reflecting an increased lymphangiogenic propensity32. Moreover our study shows a positive correlation between 
CXCR4 expression and lymph vessel presence in human atherosclerotic tissues and reduced adventitial lymph 
vessel density in mice upon CXCL12 silencing. As such, such VEGF-C/-D independent pathway may also under-
lie the unchanged adventitial lymph vessel density.
Although CXCR4 appears to be a major cue, in addition to lymphangiogenic growth factors such as VEGF-C 
and -D33, we cannot exclude the involvement of other inflammatory chemokine pathways or other VEGFR3 
independent pathways, such as stretch-dependent β 1-integrin signaling in adventitial lymphangiogenesis. The 
different pathways most likely work in concert to induce lymphangiogenesis, with an initial prominent role for 
hypoxia and inflammation driven VEGF-C/D and CXCL12 production28,29, followed by an increasing role for 
stretch-induced β 1-integrin signaling upon growth of the plaque and increasing plaque interstitial pressure31.
A second relevant question relates to the consequences of adventitial lymphatic bed expansion on plaque 
inflammation and atherosclerosis. Adventitial lymphatic capillaries could help to prevent edema, caused amongst 
others by leaky plaque vasa vasorum. In addition, as pointed out by Randolph and coworkers, lymphatics could 
exert atheroprotective functions by draining plaque contained lipids during regression21. Our study adds to this 
notion in that surgical interruption in their draining function or interference with their expansion aggravated 
Figure 4. Chemokine and lymph vessel dependent accumulation of T cells. (A) Representative Lyve-1 
staining and quantification of lymph vessel density (LVD) after perivascular treatment with siRNA targeting 
CXCL12. (B) Representative CD3 staining and quantification of adventitial T cell content after perivascular 
treatment with siRNA targeting CXCL12.
Figure 5. Correlation analysis in human endarterectomy plaque tissues. Correlation analysis between T cells 
(A) and macrophages (B) per plaque area and D2-40 positive, lymphatic area in human atherosclerotic lesions. 
(C) Correlation analysis of CXCR4 expression and D2-40 positive, lymphatic area in human endarterectomy 
plaque tissue.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:45263 | DOI: 10.1038/srep45263
disease. The atheroprotection provided by adventitial lymphatics may be partly based on their regulatory role in 
plaque T cell accumulation. Whether adventitial lymphatics control CD3+ T cell accumulation directly, by medi-
ating egress (as suggested by their close proximity to the adventitial lymph vessels, data not shown), or indirectly 
by draining T cell chemotactic cues remains to be determined. Dissecting the exact mechanism is complicated 
by the reciprocal interaction between lymph vessels and T cells with lymph vessels steering T cell trafficking (this 
study), and T cells in turn inhibiting lymphangiogenesis34.
In conclusion, this study shows that adventitial lymphatic vessels increased at an early stage of plaque devel-
opment, conferring a protective role by draining and therefore dampening the local inflammatory response. 
Draining lymph node dissection resulted in aggravation of atherosclerosis, accompanied by increased plaque 
and adventitial T cell content, probably due to interrupted T cell egress or reduced draining of chemotactic cues. 
Adventitial lymphangiogenesis could not be halted by VEGF-C/D inhibition, but was at least partly arrested due 
to non-classical lymphangiogenesis via the CXCL12/CXCR4 axis. Further studies are needed to provide further 
insight into the precise role and mechanisms of adventitial lymphatic capillary formation in atherosclerosis, and 
their potential impact on clinical outcome.
Methods
Immunohistochemistry. Human carotid artery plaque tissue was obtained by endarterectomy, for more 
detail see ref. 35. For studying adventitial lymph vessels, human aortic plaque tissue was obtained during kidney 
transplantation, as described previously36. Collection, storage and use of tissue and patient data (methods) were 
performed after informed consent and in agreement with the ‘Code for Proper Secondary Use of Human Tissue 
in the Netherlands’ and in accordance with the guidelines of, and approved by the medical and ethical committee 
of Leiden University Medical Center, Leiden, The Netherlands. Lesions were fixed in paraformaldehyde (4%) 
and paraffin embedded. Histological assessment of human atherosclerotic lesions was performed according to 
Virmani classification37. Lymph vessel analysis was performed using anti-podoplanin (D2-40) antibody (goat 
polyclonal, R&D systems), and microvessels were stained using CD31 (clone JC/70a, Dako). Vessels were then 
counted manually and corrected for plaque or adventitial area.
Immunohistochemical (IHC) staining on mouse paraffin carotid artery sections was performed for lymph 
vessel marker Lyve-1 (rabbit polyclonal, Abcam), for T cells using CD3 (DAKO), for macrophages using Mac-3 
(clone M3/74, BD), and for microvessels using CD31 (clone MEC13.3, BD).
Lyve-1+ lymphatic capillary content (scored on the basis of morphology and positive staining) was expressed 
as percentage of adventitial area. Lymphatic capillaries were defined as Lyve-1+ cells, circumventing a clearly 
identifiable lumen. The adventitial area was defined as tissue within a distance of twice the smallest intima-media 
thickness from the outer elastic lamina. The number of CD3+, CXCR3+ and Mac-3+ cells was expressed as per-
centage of total plaque or adventitial cells. IHC staining for Lyve-1 was also performed on paraffin embedded 
matrigel plugs from the AAV-hVEGFR3-Ig study (n = 5/group). Lymph vessel ingrowth into the Matrigel plugs 
was determined in three slides per plug. All slides were analyzed by a blinded observer (TR) using Leica Qwin 
software.
Analysis of adventitial lymphatic capillaries and CD3+ T cells. Male ApoE−/− mice (n = 21, 12 weeks 
of age), backcrossed at least 11 times to C57Bl/6 and obtained from The Jackson Laboratory, were placed on 
western type diet (WTD) containing 0.25% cholesterol and 15% cacao butter (Special Diets Services, Witham, 
Essex, UK). Atherosclerotic carotid artery lesions were induced by bilateral placement of semi-constrictive col-
lars38. To study adventitial lymphatic capillary density and CD3+ T cell content in early (n = 9) and advanced 
lesions (n = 6), mice were sacrificed 4 and 8 weeks after collar placement, respectively. Naïve carotid artery seg-
ments from ApoE−/− mice, not equipped with a perivascular collar (20 weeks of age) served as control (n = 6). 
All animal experiments were approved by the ethics committee of Maastricht University Medical Center (DEC 
2010–098 and 2011–093, Maastricht, The Netherlands) and performed according to institutional guidelines.
Lymph node and vessel dissection in mice. Male ApoE−/− mice (n = 27, 12 weeks of age) were placed 
on WTD and semi-constrictive collars were placed around the carotid arteries to induce atherosclerosis devel-
opment38. To address the impact of the deep cervical lymph node drainage to leukocyte influx into and efflux 
from the adjacent plaque, the lymph node and efferent lymph vessel were removed immediately after collar place-
ment (n = 14). Mice which received only collar placement (n = 13) served as control. At sacrifice, mice from the 
lymph node dissection group did not show any signs of edema in the neck region. In a separate study we inves-
tigated whether lymph node/vessel dissection per se induces a local inflammatory response, which could impact 
lesion formation indirectly. Hereto, we studied effects of the above intervention in normolipidemic wild-type 
mice (n = 5–6, 12 weeks of age). Both hyper- and normolipidemic mice were sacrificed at 4 weeks after collar 
placement.
Pharmacological inhibition of lymphangiogenesis in mice. Male ApoE−/− mice (n = 34, 12 weeks 
of age) were placed on WTD and semi-constrictive collars were placed bilaterally, proximal to the bifurcation 
of the carotid artery for shear-dependent atherosclerosis induction38. To inhibit VEGFR3-dependent adventitial 
lymphangiogenesis during plaque development, adeno-associated virus (AAV) encoding a soluble hVEGFR3-Ig 
(AAV-hVEGFR3-Ig, 1011 virus particles per mouse27) or control virus (AAV-hVEGFR3(D4-7)-Ig) was adminis-
tered systemically by intravenous injection at the time of collar placement (n = 17 hVEGFR3-Ig vs. n = 17 con-
trol). Mice were sacrificed 4 weeks after collar placement.
A subgroup of mice (n = 5 per group) also received a subcutaneous plug of VEGF-C supplemented Matrigel 
(BD Bioscience) to validate the efficacy of lymphangiogenesis inhibition by the hVEGFR3-Ig construct. In 
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addition, blood was isolated at 4 weeks after collar placement, serum was obtained by centrifugation (10 min, 
1,500 g, 4 °C), and plasma transgene expression was assessed by ELISA and western blot.
Focal silencing of adventitial CXCL12 expression. Male ApoE−/− mice (12 weeks of age) were placed 
on WTD (0.15% cholesterol, Altromin, Lage, Germany) for 6 weeks after which semi-constrictive collars were 
placed around the carotid arteries to induce atherosclerosis. To address the contribution of adventitial CXCL12 
to atherosclerosis development, mice were perivascularly treated with a CXCL12 specific siRNA or non-targeting 
siRNA control (once weekly, 4 nmol, dissolved in plurogenic gel; Dharmacon) as previously described39.
Histology of mouse atherosclerotic lesions. Mice were euthanized by pentobarbital injection (115 mg/kg) 
and perfused through the left cardiac ventricle with PBS (NaCl/Na2HPO4/KH2PO4, pH 7.4) containing sodium 
nitroprusside (0.1 mg/ml, Sigma) and 1% paraformaldehyde (PFA). The right carotid artery was removed, fixed 
overnight in 1% PFA and paraffin-embedded sections (4 μ m) were cut. To determine plaque volume in the carotid 
artery, sections were stained for haematoxylin and eosin (HE) and plaque area was measured for consecutive 
cross-sections, at 100 μ m intervals, over a carotid artery segment that covered the entire plaque. Slides were ana-
lyzed in a blinded manner using a Leica DM3000 light microscope (Leica Microsystems) coupled to computer-
ized morphometry (Leica Qwin 3.5.1)40. Size and progression stage of atherosclerotic lesions was determined 
as previously described41, with minor modifications. Plaques were classified as early (foam cell rich, but lacking 
a necrotic core), moderately advanced (containing a fibrotic cap and often a necrotic core, but no medial mac-
rophage infiltration) and advanced lesions, typified by medial macrophage infiltrates, elastic lamina degrada-
tion and more pronounced necrosis and fibrosis. HE sections were used for morphometric analysis and routine 
qualitative examination of collagen content, necrosis, foam cell content and amount of inflammatory cells (using 
scores from 0 (absent) to 3 (high abundance)).
Flow cytometry and plasma total cholesterol measurement. Blood, spleen and lymph nodes were 
removed before perfusion (n = 10/group) and used for flow cytometry of monocytes (CD11bhigh Ly6G−, BD), 
granulocytes (CD11bhigh Ly6Ghigh, BD), T helper cells (CD4+, BD), effector T cells (CD8a+,BD) and activated T 
cells (CD44high, eBioscience). Briefly, spleen and lymph nodes were homogenized, filtered through a 70 μ m mesh. 
Blood, spleen and lymph nodes were subjected to red blood cell lysis. All cells were stained in flow cytometry 
buffer (1xPBS, 0.5% BSA, 0.01% NaN3). Staining for blood count analyses was conducted using antibodies to 
CD45, CD115, Gr1, CD19, and CD3 (all eBiosciences) in Hank’s Balanced Salt Solution (HBSS) with 0.3 mM 
EDTA and 0.1% bovine serum albumin (BSA). Cell counts were estimated utilizing CountBrightTM absolute 
counting beads (Invitrogen). All flow cytometry analysis was performed on a FACS CANTO II (BD Bioscience).
Statistical analysis. Data are expressed as mean ± SEM. For correlation analyses of human expression data, 
Shapiro-Wilk test for normality was performed, after which correlations of Gaussian distributed data were cal-
culated by Pearson and of non-Gaussian data by Spearman correlation test. For group comparisons, data were 
tested for Gaussian distribution, after which a Student t-test (Gaussian) or Mann-Whitney U test (non-Gaussian) 
was used to compare individual groups; multiple groups were compared by ANOVA or Kruskall-Wallis tests, with 
Bonferroni or Dunn’s post-hoc test, respectively. Statistics were performed using Graphpad Prism 5.0. A p-value 
of < 0.05 was considered statistically significant. *Denotes p < 0.05, **denotes p < 0.01, ***denotes p < 0.001.
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